We are delighted to announce our collaboration with Lundbeck, a global pharmaceutical company specialized in brain diseases. We are working to provide a new model to develop drugs for devastating neurodegenerative movement disorders using the nematode worm C. elegans. The model, made by expressing human genes found in patients will enable Lundbeck to find new interventions which, like the disease, act during development.
Neurodegeneration produces behavioural changes with profound effects on quality of life that cannot be replicated in in vitro models. Testing compounds that could slow the degeneration of neurons in a mammalian model are limited by time, expense and regulation. Magnitude Biosciences use the nematode worm C. elegans to quickly generate models of neurodegenerative disease through overexpression of human proteins implicated in neurodegenerative diseases, which leads to loss of function phenotypes that can be scored and used to test interventions. Our automated data acquisition, robust methodology and processes help us conduct experiments quickly with high reproducibility. Lundbeck approached Magnitude Biosciences as a world- leading C. elegans CRO. This collaboration is an example that we can adapt to the needs of a wide range of disease-specific challenges in drug discovery.
"We are excited to be working with Magnitude Biosciences. Their unique approach to generating in vivo data for studying disease models will hopefully help us get fast and reliable answers to our research questions."- Kjartan Herrik, Principal Scientist at Lundbeck
Please look out for the results of this collaboration, which will be shared in the public domain.